Pharmaids Pharmaceuticals Ltd.
BSE: PHARMAID · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Pharmaids Pharmaceuticals Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Pharmaids Pharmaceuticals Limited is an Indian company engaged in the manufacturing, marketing, and distribution of diverse pharmaceutical formulations. Its product portfolio includes tablets, capsules, and liquid orals across therapeutic segments such as anti-infectives, analgesics, and nutritional supplements.
Business Model
The company generates revenue through the production and sale of pharmaceutical products, leveraging its manufacturing capabilities and domestic trade distribution networks. It is currently exploring expansion into contract manufacturing to scale its operations.
Management Commentary
Management is focused on expanding the company's market footprint by exploring opportunities in contract manufacturing and the development of specialized healthcare products.
Growth Outlook
Growth is expected to be driven by the diversification of the product portfolio and the strategic pursuit of contract manufacturing partnerships within the Indian life sciences sector.
Key Risks
- Regulatory Compliance. The pharmaceutical industry is subject to stringent regulatory oversight, and failure to comply with manufacturing standards could disrupt operations.
- Market Competition. The company faces intense competition from both large-scale pharmaceutical firms and other small-cap entities in the domestic market.
- Input Cost Volatility. Fluctuations in the prices of raw materials and active pharmaceutical ingredients can significantly impact profit margins.
Start your research today
Unlock AI insights, financials, peers and live data on Pharmaids Pharmaceuticals Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹28 Cr
TTM · consolidated
NET PROFIT
₹12 Cr
TTM · consolidated
EPS
₹3.32
TTM · consolidated
RETURN ON EQUITY
20.5%
TTM · consolidated
P/E
9.1x
Q4 FY26 · consolidated
EV/EBITDA
5.2x
Q4 FY26 · consolidated
EBITDA MARGIN
87.8%
TTM · consolidated
NET PROFIT MARGIN
15.0%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.4x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Pharmaids Pharmaceuticals Ltd.PHARMAID | ₹106 Cr | 9.08 | 5.18 | 43.8% | 87.8% | 20.5% | 23.7% | -47.6% |
TranschemTRANSCHEM | ₹502 Cr | 75.62 | 52.99 | -100.0% | 177.7% | 8.3% | 10.6% | +600.8% |
Albert DavidALBERTDAVD | ₹501 Cr | 21.67 | 13.19 | 11.4% | 11.0% | 5.8% | 7.5% | +10.3% |
Haleos Labs LimitedHALEOSLABS | ₹457 Cr | 28.51 | 12.83 | -3.1% | 13.6% | 7.4% | 10.3% | — |
Medicamen BiotecMEDICAMEQ | ₹434 Cr | 43.00 | 19.76 | 24.7% | 11.3% | 4.1% | 6.2% | +5.9% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹420 Cr | 12.30 | 8.20 | — | 30.0% | 16.7% | 21.5% | -15.2% |
As of Q4 FY26
Financials
Pharmaids Pharmaceuticals Ltd.
BSE: PHARMAID · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Pharmaids Pharmaceuticals Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Pharmaids Pharmaceuticals Limited is an Indian company engaged in the manufacturing, marketing, and distribution of diverse pharmaceutical formulations. Its product portfolio includes tablets, capsules, and liquid orals across therapeutic segments such as anti-infectives, analgesics, and nutritional supplements.
Business Model
The company generates revenue through the production and sale of pharmaceutical products, leveraging its manufacturing capabilities and domestic trade distribution networks. It is currently exploring expansion into contract manufacturing to scale its operations.
Management Commentary
Management is focused on expanding the company's market footprint by exploring opportunities in contract manufacturing and the development of specialized healthcare products.
Growth Outlook
Growth is expected to be driven by the diversification of the product portfolio and the strategic pursuit of contract manufacturing partnerships within the Indian life sciences sector.
Key Risks
- Regulatory Compliance. The pharmaceutical industry is subject to stringent regulatory oversight, and failure to comply with manufacturing standards could disrupt operations.
- Market Competition. The company faces intense competition from both large-scale pharmaceutical firms and other small-cap entities in the domestic market.
- Input Cost Volatility. Fluctuations in the prices of raw materials and active pharmaceutical ingredients can significantly impact profit margins.
Start your research today
Unlock AI insights, financials, peers and live data on Pharmaids Pharmaceuticals Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹28 Cr
TTM · consolidated
NET PROFIT
₹12 Cr
TTM · consolidated
EPS
₹3.32
TTM · consolidated
RETURN ON EQUITY
20.5%
TTM · consolidated
P/E
9.1x
Q4 FY26 · consolidated
EV/EBITDA
5.2x
Q4 FY26 · consolidated
EBITDA MARGIN
87.8%
TTM · consolidated
NET PROFIT MARGIN
15.0%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.4x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
As of Q4 FY26